Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
Conditions
Interventions
Intervention1: UNIM 401: 500 mg capsule of UNIM 401 will be taken twice daily with water for six month
Control Intervention1: Healthy volunteer: healthy volunteers will be compared with psoriasis pati
Sponsors
Central council for Research in Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: Patients with clinically diagnosed Psoriasis and healthy controls with matched temperament. Age: 20-50 years. With any duration of the disease, site, extension and distribution of the lesions. Willingness to give written informed consent form.
Exclusion criteria
Exclusion criteria: Subjects with Psoriasis treatment with other drug /systems. History of drug or alcoholic abuse, chronic smokers not willing to abstain from smoking during the study period. Any clinically significant abnormality identified on physical examination/laboratory tests. Subjects having any systemic disease and other skin diseases. Subjects with known allergies. Impaired cardiac, hepatic and renal function. History of malignancy. Concomitant use of any other antioxidants. Pregnant and other lactating women. Pregnant and other lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The present study will provide an understanding about the cellular level via multiple arms (ant proliferative, pro-apoptotic, anti-inflammatory, anti-antigenic) of UNIM formulation (UNIM401). It also provides insight into mechanism of action of formulation & highlights its promising potential for development as an herbal therapeutic agent for psoriasis, emphasizing the need of further pharmacological evaluation & toxicological studies Timepoint: 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| The present study will provide an understanding about the cellular & molecular mechanism of Unani formulation (UNIM 401) being used for treatment of various diseases from centuries keeping in mind the Unani Philosophy. Further the study will help in validation of their safety and anti-inflammatory properties. Exploration of cellular and molecular mechanism involved in anti-inflammatory properties and the scientific validation in terms of mechanistic study for Unani drug will help to create an evidence based data and will pave the way for acceptability of these drugs globally Timepoint: 3 years | — |
Countries
India
Contacts
Public ContactDrTasleem Ahmad
National Research Institute of Unani Medicine for Skin Disorders
Outcome results
None listed